medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2005, Number 4

<< Back Next >>

Rev Mex Patol Clin Med Lab 2005; 52 (4)

Current state of the hormonal replacement therapy with dehydroepiandrosterone

Terrés SAM

Language: Spanish
References: 79
Page: 210-221
PDF size: 190.70 Kb.


ABSTRACT

Background: According to the WHO, aging is one of the greatest global public health challenges. On any medical approach, from prevention to therapy, physiopathological understanding of disease mechanisms is necessary not only to achieve success, but also, to avoid undesired complications that in the case of aging represent a broad spectrum of chronic diseases that may condition catastrophic costs in terms of treatment and rehabilitation. Goal: To establish the state of the art of DHEA’s role on aging process including the diagnostic and therapeutical perspectives. Methodology: This is a bibliographic review of relevant national and international medical publications. Results: DHEA is an adrenal, cerebral and gonadal steroid derived from cholesterol and precursor of sexual hormones. Plasma and serum levels of DHEA-S have been extensively used on Cushing Syndrome, Congenital Adrenal Hyperplasia And Adrenal Tumors Including Virilization, Hirsutism, Polycystic Ovarian Syndrome and several Psychiatric Problems Including Depression A novel application for this test is chronobiological marker for aging evaluation. For this purpose it is convenient to consider gender and age measured as decade in order to compare obtained results with pre-established chronobiological reference limits. Conclusions: There are many not-answered questions and doubts surrounding DHEA. Even when it seems clear that it is playing an important role on aging process it is difficult to assure that nutritional supplementation on low doses or pharmacological intake on high doses will have a positive impact on longevity that depends on bio-psycho-social harmony and psycho-neuro-immune-endocrine (PNIE) homeostasis that we are just recently starting to understand. Even though that DHEA is being used extensively as an ant aging nutraceutical we still need a solid, scientific, prospective, long-range protocol in order to define the precise role and capacity to extend longevity and to improve the quality of human life.


REFERENCES

  1. Core Health Indicators. Who Statistical Information Systems. www.who.int

  2. Organización Panamericana de la Salud. Envejecimiento y salud: Un cambio de paradigma. Rev Panam Sal Publ 2000; 7:60-7

  3. CONAPO. Proyecciones de la población de México, 2000-2050. INEGI/Secretaría de Salud. Dirección General de Información en Salud. 2002

  4. Kalache A. ¿Qué repercusiones tiene el envejecimiento de la población en el futuro posible? En: Pérez EA (ed). La atención de los ancianos: Un desafío para los años noventa. OPS, Publicación Científica No. 546, 1994.

  5. Crimmins EM, Hayward MD, Saito Y. Changing mortality and morbidity rates and the health status and life expectancy of the older population. Demography 1994; 31 (3): 159-175

  6. Villanueva ELA. Sobre el envejecimiento: una perspectiva integral. Rev Hosp Gral M Gea Glz 2000; 3 (3): 107-114.

  7. Olshansky SJ, Carnes BA, Cassel CK. The aging of the human species. Scientific Am 1993; 268: 46-52.

  8. Secretaría de Salud. Encuesta nacional de enfermedades crónicas. México: Dirección General de Epidemiología, SS, 1993.

  9. Borges-Yáñez SA, Gómez-Dantés H. Uso de los servicios de salud por la población de 60 años y más en México. Sal Pub Mex 1998; 40: 13-23.

  10. Barros Lazaeta C. Aspectos sociales del envejecimiento. En: Pérez EA (ed). La atención de los ancianos: Un desafío para los años noventa. OPS, Publicación Científica No. 546, 1994.

  11. Kalache A, Coombes Y. Population aging and care of the elderly in Latin America and the Caribbean. Rev Clin Gerontol 1995; 5: 347.

  12. Wilmoth JR, Deegan LJ, Lundstrom H, Horiuchi S. Increase of maximum life-span in Sweden: 1861-1991. Science 2000; 289: 2366-2368.

  13. Kurtzman J, Gordon P. En: Homo Longevus. La prolongación de la vida humana. 3a ed. México: Láser Press Mexicana, 1982; 22.

  14. Gutiérrez LM. El proceso de envejecimiento humano: implicaciones clínicas y asistenciales. Rev Fac Med UNAM 1998; 41: 198-206.

  15. Burns EA. Immunodeficiency of aging. Drug and Aging 1997; 5: 374-397.

  16. Ginaldi L. Immunological changes in the elderly. Aging Clin Exp Res 1999; 11: 281-286.

  17. Campisi J. Aging and cancer. J Am Geriatric Soc 1997; 45: 482.

  18. 17a. Miller RA. The aging immune system: Primer and prospectus. Science 1996; 273: 70.

  19. Sohal RS, Weindruch R. Oxidative stress, caloric restriction and aging. Science 1996; 273: 59.

  20. Miller RA. The biology of aging and longevity. En: Hazzard WR, Blass JP, Ettinger WH, Halter JB, Ouslander JG (eds). Principles of geriatric medicine and gerontology. 4th ed. USA: Mc Graw-Hill, 1999.

  21. Terrés Speziale AM. Homo longevus: El paradigma del envejecimiento sano. Rev Mex Patol Clin 2005; 52 (1): 27-39.

  22. Ferrari E, Magri F, Migliorati G, Dori D, Molla G, Nescis T, Floravanti M, Soferte SB. Neuroendocrine correlates of the aging brain in humans. Neuroendocrinology 1995; 61: 464-670.

  23. Corpas E, Harman S, Blackman MR. Human growth hormone and human aging. Endocrin Rev 1993; 14: 20-39.

  24. Fonseca E, Ochoa R, Galvan R, Hernandez M, Mercado M, Zarate A. Increased serum levels of growth hormone and insulin-iike growth factor-1 associated with simultaneous decrease of circulating insulin in postmenopausal women receiving hormone replacement therapy. Menopause 1999; 6: 56-60.

  25. Osorio A, Vara-Thorbeck R, Rosell J, Osorio C, Ortega E, Ruiz-Requena E. Dehydroepiandrosterone sulfate and groth axis hormones in patients after surgery. World J Surgery 2002; 26 (9): 1079-1082.

  26. Zárate A. Longevidad y menopausia. En: Zárate A, MacGregor C (eds). Menopausia y cerebro. México: Editorial Trillas, 1998; 13-18.

  27. Wise P, Kranjnak KM, Kashoon ML. Menopause. The aging of multiple pacemarkers. Science 1996; 273: 67-70.

  28. Mor G, Naftolin F. Estrogen, Menopause and the immune system. Menopause 1998 (suppl 1): 4-8.

  29. Rosen RC, Taylor JF, Leiblum SR, Bachmann GA. Prevalence of sexual dysfunction in women: Results of a survey study of 329 women in an outpatient gynecological clinic. J Sex Marital Therapy 1993; 19: 171-188.

  30. Slayden SM, Brabbe L, Bae S, Potter HD, Azziz R, Parker CR. The effect of 17B-estradiol on adrenocortical sensitivity responsivennes and steroidogenesis in postmenopausal women. J Clin Endocrinol Metab 1998; 83: 519-524.

  31. Tenover J.L Testosterone and the aging male. J Andrology 1997; 18: 103-106.

  32. Tenover JL. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metabol 1992; 73: 1092.

  33. Vermeulen A. Androgens in the aging male. Clinical Review 24. Clin Endocrinol Metabol 1991; 73: 221-224.

  34. Altman Alan. Androgen deficiency syndrome and female sexual dysfunction: Epidemiologic and clinical overview. Symposium 6. Desire, arousal and testosterone. In: Proceedings of the Female Sexual Functions Forum meeting, Boston, 2000: 190.

  35. Traish AM, Kim N, Min K, Munárriz R, Goldstein I. Androgens in female genital sexual arousal function: a biochemical perspective. J Sex Marital Therapy 2002; 28 (Suppl 1): 233-244.

  36. López MA, Boullosa O, Illa G, Vieitez A, Willis A, Márquez C. Dehidroepiandrosterona. Aspectos psiconeuroinmunoendocrinológicos. ALCMEON 1999; 8 (10): 29.

  37. Terrés Speziale AM et al. Importancia de los marcadores biológicos en cronobiomedicina. Rev Mex Patol Clin 2001; 48 (2): 54-64.

  38. Terrés Speziale AM. Marcadores biológicos de envejecimiento. Rev Mex Pat Clin 2000; 47 (2): 119-120.

  39. Halberg F. Chronobiology. Ann Rev Physiology 1969; 31: 675-725.

  40. Touitou Y. Chronobiological approach of aging. 1996; 44: 534-546.

  41. Dean W. Biological aging measurement. Geronto Geriatrics 1998; 1: 64-85.

  42. Terrés Speziale AM, Martínez ME. Cronobiología: Niveles hormonales en mujeres mexicanas. Rev Med IMSS 2000; 37 (5); 341-348.

  43. Terrés Speziale AM. Marcadores biológicos de envejecimiento en el hombre mexicano. Rev Med IMSS 2001; 39 (3): 199-206

  44. Zárate A, Saucedo R, Hernández M. Lugar de la terapia de reemplazo hormonal para la mujer menopáusica en la actualidad. Act Med Gpo Ang 2004; 2 (2): 129-130.

  45. Zárate A, Hernández M, Basurto L. Estado actual del tratamiento hormonal en la menopausia. Rev Fac Med (Mex) 2005; 48 (1): 14-17.

  46. Mendoza PN, León RJA ¿Sigue siendo válida la recomendación de la terapia hormonal sustitutiva? Rev Fac Med (Mex) 2005; 48 (4): 163-164.

  47. Davis S et al. Clinical Review 82: Androgens and the postmenopausal woman. J Clin Endrocrinol Metab 1996; 81: 2759-2763.

  48. Mortola F, Yen SC 1990. The effects of oral dehydroepiandrosterone on endocrine metabolic parameters in postmenopausal women. J Clin Endocrinol Metab 1990; 71: 696-704.

  49. Espeland MA, Hogan PE, Fineberg SE, Howard G, Schrott H, Waclawiw MA, Bush TL. Effect of postmenopausal hormone therapy on glucose and insulin concentrations PEPI investigators. Postmenopausal estrogen/progestin interventions. Diabetes Care 1998; 21: 1589-1595.

  50. 48a.Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. Arch Inter Med 1996; 156: 2213-2217.

  51. Guay AT and Jacobson J. Decreased free testosterone and Dehydroepiandrosterone–sulfate (DHEAs) levels in women with decreased libido. J Sex Marital Ther 2002; 28 (suppl 1): 129-142.

  52. Ridson G. Mechanisms of Chemoprevention by Dietary DHEA. Am J Pathology 1990: 136; 759-769.

  53. Regelson W. DHEA: Some Thoughts as to its Biologic and Clinical Action. In: Kalmi M (ed). Biologic role of DHEA. NY: Walter de Gruyter, 1990: 405-445.

  54. Meikle W et al. Adrenal androgen secretion and biologic effects. Endocrinol Metab Clin N Am 1991; 20 (2).

  55. Nestler J et al. Metabolism and actions of dehydroepiandrosterone in humans. J Steroid Biochem Molec Biol 1991; 40: 599-605.

  56. Stahl F: DHEA Levels in patients with prostatic cancer, heart diseases, and surgery. Exp Clin Endocrinol 1992; 99: 68-70.

  57. Haffner SM, Newcomb PA, Marcus PM, Klein BEK, Klein R. Relation of sex hormones and dehydroepiandrosterone sulfate (DHEA-S) to cardiovascular risk factors in postmenopausal women. Am J Epidemiology 1995; 142: 925-954.

  58. Hornsby PJ. Biosynthesis of DHEA-S by the human adrenal cortex and its age related decline. In: Bellino FL et al. DHEA and aging. NY: Annals of the NY Acad of Sci, 1995; 29-46.

  59. Feldman HA, Johannes CB, McKinlay JB, Longcope C. Low DHEA-S and heart disease in middle-aged men: Cross-sectional results from the Mass Male Aging Study. Ann Epidemiol 1998; 217-228.

  60. Tilvis RS, Kahonen M, Harkonen. Dehydroepiandrosterone sulfate, disease and mortality in general ages population. Aging: Clinical and Experimental Research 1999; 11: 30-34.

  61. Burtis CA, Ashwood ER. Tietz textbook of clinical chemistry. 3rd ed. Philadelphia, PA: WB Saunders, 1999.

  62. Derksen J et al. Identification of Virilizing Adrenal Tumors in Hirsute Women. N Engl J Med 1994; 331: 968-1016.

  63. Invitti C et al. Increased urinary free cortisol and decreased serum corticosteroid-binding globulin in polycystic ovary syndrome. Acta Endrocrinol 1991; 125: 28-32.

  64. Claudine B et al. Relationships of dehydroepiandrosterone sulfate in the elderly with functional, psychological, and mental status, and short-term mortality: A French community-based study. Proc Natl Acad Sci USA 1996; 93: 13410–13415.

  65. Helzlsour KJ et al. Relationship of prediagnostic serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing premenopausal breast cancer. Cancer Res 1992; 52: 1-4.

  66. NCCLS. Approved Guideline–Evaluation of precision performance of clinical chemistry devices, EP5-A. 1999.

  67. Terrés Speziale AM. El laboratorio clínico y la evaluación del riesgo coronario. Rev Mex Pat Clin 2000; 47 (4): 202-218.

  68. Terrés Speziale AM, Bello Madrigal NM. Lípidos: Aplicación de niveles de decisión clínica y evaluación de su cronobiología en México. Rev Med IMSS (En Prensa).

  69. Terrés Speziale AM, Canahuati Rock L. Aterogénesis y glicosilación de las proteínas en diabetes mellitus. Rev Mex Patol Clin 1996; 43: 67-79.

  70. Chrorousos GP et al: Stress Basic Mechanisms and Clinical Implications. Annals of The New York Academy of Sciences. Vol 771. 1995.

  71. Boudarene M, Legros JJ, Timsit-Berthier M. Study of the stress response: Role of anxiety, cortisol and DHEAs. Encephale 2002; 28 (2): 139-146.

  72. Nasu M, Toshitsugu S, Chihara M, Hiraumi M, Kurimoto F, Chihara K. Effect of natural menopause on serum levels of IGF-1 and IGFbinding proteins: relationship with bone mineral density and lipid metabolism in perimenopausal women. Eur J Endocrinol 1997; 136: 608-616.

  73. Peck WA. Consensus Development Conference: Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993; 94: 646-650.

  74. Riggs BL, Melton LJ III. Involutional osteoporosis. N Engl J Med 1986; 314: 1676-1686.

  75. Kanis JA. Causas de la osteoporosis. En: Kanis JA (ed). Osteoporosis. Londres: Blackwell Science, 1996; 93-129.

  76. Tamayo et al. How Frequent is Osteoporosis? J Bone Mineral Res 1997.

  77. Kanis JA. Bone density measurement: A systemic review. J Intern Med 1997; 739: 1-60.

  78. Terrés Speziale AM. Edad ósea: Estimación densitométrica y metabólica. Rev Mex Patol Clin 2002; 49 (1): 7-14.

  79. Bente JR. Biochemical markers of bone turnover in diagnosis and assessment of therapy. Am J Med 1991; 58: 645-685.




2020     |     www.medigraphic.com